W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel

drops may be prepared; for vaginal administration they may be prepared as
pessaries, tampons, creams, gels, pastes, foams or spray formulations; for
parenteral administration, aqueous and non-aqueous sterile injectable
solutions or suspensions may be prepared.
In a particularly preferred embodiment, the compounds of the invention are
administered topically, for instance, in the form of ointments, creams,
suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.
The present invention will be further better detailed in the following
Experimental Section.
EXPERIMENTAL SECTION
Synthesis- General Information
NMR spectra were recorded at 25°C and 30 °C with Bruker spectrometers.
Chemical shifts 1 H and 13 C NMR spectra are expressed in ppm relative to TMS
or to DSS for spectra recorded in D 2 O. The cyclohexanediol moiety is
numbered as in Fig. 5. Subscripts D refer to the cyclohexanediol (ps-Man)
residue of 7 and 9 and 2 . Mass spectrometry was performed with a
ThermoFisher LCQ apparatus (ESI ionization), or ion-trap ESI Esquire 6000
from Bruker, or an Microflex apparatus (MALDI ionization) from Bruker, or
Apex Il ICR FTMS (ESI ionization - HR-MS). Optical rotations [α] D were
measured in a 1-dm path-length cell with 1 mL capacity on a Perkin-Elmer 241
polarimeter. Thin layer chromatography (TLC) was carried out with precoated
Merck F254 silica gel plates. Unless otherwise specified the TLC were
revealed with molibdic reagent. Flash chromatography (FC) was carried out
with Macherey-Nagel silica gel 60 (230-400 mesh). Final dendritic compounds
were purified by size exclusion chromatography using sephadex LH20 from GE
Healthcare Life Science. Solvents were dried by standard procedures and